Great success has been achieved in the clinical study conducted on supportive treatment of Irritable Bowel Syndrome, which affects almost 15% of people. In the clinical study conducted by ENBIOSIS, which is a local biotechnology startup that develops personalized nutrition programs by analyzing bacteria in the human gut using microbiome tests, 78% of the patients with Irritable Bowel Syndrome have shown improvements.
Studies on the relationship between the microbiome (the bacteria in the gut) and human health have been increasing rapidly all over the world. ENBIOSIS, a local biotechnology initiative, aims to develop personalized health solutions for the treatment of several health problems, such as obesity, diabetes, and eczema, by studying bacteria in the human gut. ENBIOSIS has achieved significant success with its clinical study on IBS, commonly known as Irritable Bowel Syndrome, by participating in the studies carried out in this field. According to the statement made by ENBIOSIS, it was reported that symptoms were observed to have improved in 78% of the IBS patients who were administered personalized diets. This result was evaluated as a significant scientific finding suggesting that a microbiome-based diet could be promising in the treatment of IBS. Ethical committee approval was obtained from Gazi University.
In his statement on the details of the clinical study, Mr. Ozkan Ufuk Nalbantoglu, the CTO of ENBIOSIS said, “In the first phase of our study, which was conducted upon the ethics committee approval obtained from Gazi University, stool samples were collected from patients who were diagnosed with Irritable Bowel Syndrome and met the inclusion criteria for the study, and microbiome analyses were performed on these samples. Then, the patients were divided into two groups. The first group was administered the microbiome-based personalized diet developed by ENBIOSIS and followed up by dietitians for 6 weeks. The second group, which was the control group, was followed up with a standard diet for 6 weeks. I would like to mention that the diets in the ENBIOSIS diet group were not developed according to the elimination diets commonly used in the treatment of IBS. Rather, personalized diets were developed with alternatives based on each individual’s microbiome. In some cases, the needs were related to grain sources that contained mainly gluten, while others were mostly related to vegetables, and still others required certain fat sources or protein sources. At the end of 6 weeks, stool samples were collected from both groups, and microbiome analyses were performed and compared with the results from the first samples.”
The study will be presented at an international conference.
Concerning the results of the study, Mr. Ufuk Nalbantoglu said, “The clinical conditions of the patients were monitored concurrently for 6 weeks, and pre-diet and post-diet scores (IBS-SSS) were calculated by the gastroenterology specialists who participated in the study. At the end of the study, we observed statistically significant improvements in the ENBIOSIS diet group compared to the standard diet group in terms of both microbiome profile and clinical findings. While all patients had severe symptoms at the beginning of the study, the gastroenterology specialists reported that the symptoms regressed from severe to moderate in 78% of the patients in the ENBIOSIS diet group. Similarly, it was determined that there were significant changes in the microbiome profile of the patients in the ENBISOS diet group in certain bacterial groups characterized by IBS compared to the other group. We would like to announce these results to the science arena as soon as possible. As a team, we have begun writing the article, and plan to present the results at an international conference before it is published.”
The power of personalized health solutions has been proven.
Emphasizing that they aim to expand prevention and treatment support approaches using the gut microbiome, Nalbantoğlu said, “An increasing number of scientific studies have recently indicated that the bacterial balance in the gut is associated with many diseases. As ENBIOSIS, we aim to support the treatment process of diseases such as Crohn’s disease, ulcerative colitis, irritable bowel syndrome, obesity, and eczema using personalized diets developed based on the literature and current studies. In this context, we first analyze the bacteria in the gut and map the current condition. Then, we determine the foods that should be consumed to achieve a healthy condition or ensure bacterial balance on an individual basis. With our clinical study on IBS, we believe that we have made an important advancement for the literature. We are proud of this study, particularly because it proves the power of microbiome-based personalized health solutions. The achievements of ENBIOSIS are also closely followed up in the global arena. Recently, we were chosen 1st place among 114 global start-ups at the “When Healthtech Meets Insurance” event held by NN Insurance.”